Adaptive Biotechnologies
ADPT
200 hedge funds and large institutions have $709M invested in Adaptive Biotechnologies in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 58 increasing their positions, 73 reducing their positions, and 26 closing their positions.
42% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 26
5% more funds holding
Funds holding: 190 → 200 (+10)
2.23% more ownership
Funds ownership: 97.64% → 99.87% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less capital invested
Capital invested by funds: $769M → $709M (-$60.8M)
21% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 73
32% less call options, than puts
Call options by funds: $482K | Put options by funds: $710K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$13.1M |
| 2 |
Morgan Stanley
New York
|
+$6.77M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$5.92M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$4.26M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.08M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$5.83M |
| 3 |
Goldman Sachs
New York
|
-$4.08M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$3.44M |
| 5 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$3.15M |
ADPT Hedge Fund Activity: Q4 2023 in Review
200 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q4 2023, worth a combined $709M — down 7.9% from $769M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ADPT positions and 26 closed out — a net gain of 11 holders — while 58 added to existing stakes and 73 trimmed.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $13.1M. The largest seller was Point72 Asset Management, cutting an estimated $9.08M.
- 200 institutional investors held Adaptive Biotechnologies (ADPT) as of Q4 2023, up from 190 in Q3 2023.
- Funds reported $709M of Adaptive Biotechnologies stock for Q4 2023, down 7.9% quarter-over-quarter.
- 37 funds opened new Adaptive Biotechnologies positions in Q4 2023 and 26 closed out, a net change of +11 holders.
- The largest Adaptive Biotechnologies buyer in Q4 2023 was Rubric Capital Management (New York), an estimated $13.1M added.
- The largest Adaptive Biotechnologies seller in Q4 2023 was Point72 Asset Management, an estimated $9.08M sold.
Based on aggregated 13F filings for Q4 2023.